Compare iShares Gold Trust (IAU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs GeneDx Holdings Corp — how do they compare? iShares Gold Trust trades at $78.87 (market cap $61.51B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares Gold Trust is far larger — about 30.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 3,206,729). Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and GeneDx Holdings Corp for 19 Days on average.
| IAU | WGS | |
|---|---|---|
Market Cap | $61.51B | $2.02B |
Volume | 3,206,729 | 734,640 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $167.51 |
52-Week Low | $74.21 | $34.51 |
Typical Hold Time | 49 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.87, up 2.35% today, but faces strong technical bearish signals with 13 of 13 moving averages indicating sell signals. The stock shows neutral momentum oscillators with RSI levels at 40.80 (6-day) and 31.31 (12-day) suggesting potential oversold conditions. Recent market sentiment reflects gold's sensitivity to interest rate expectations and Treasury yield movements.
Investment outlook remains cautious with technical indicators predominantly bearish and gold prices facing headwinds from rising yields. The stock's proximity to key support at $76-77 creates a critical level to watch, while Federal Reserve policy decisions on interest rates will likely drive near-term direction.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
